Inoue, Mariko
Nagafuchi, Yasuo
Ota, Mineto
Tsuchiya, Haruka
Tateishi, Shoko
Kanda, Hiroko
Fujio, Keishi
Article History
Received: 3 March 2023
Accepted: 8 September 2023
First Online: 14 September 2023
Competing interests
: MI has received speaking fees and/or honoraria from Asahi Kasei and Daiichi Sankyo. YN belongs to the Social Cooperation Program, Department of Functional Genomics and Immunological Diseases, supported by Chugai Pharmaceutical, and has received financial support and/or speaking fees from Abbvie, BMS, Chugai, GlaxoSmithKline, Kissei, Mitsubishi Tanabe, Novartis, and Pfizer. MO belongs to the Social Cooperation Program, Department of Functional Genomics and Immunological Diseases, supported by Chugai Pharmaceutical. HT has received speaking fees and/or honoraria from Tanabe Mitsubishi, Janssen, Daiichi Sankyo, Amgen, Eisai, Gilead, Bristol-Myers Squibb, Asahi Kasei, Sanofi, UCB, Abbvie, and Eli Lilly, and has received grants from Abbvie, Mochida, and Takeda. ST declares no conflicts of interest. HK has received speaking fees and/or honoraria from AbbVie, Asahi Kasei, AstraZeneca, Astellas, Ayumi, Bristol Myers, Chugai, Eisai, Eli Lilly, Daiichi-Sankyo, Janssen, Novartis, Nihon Kayaku, Pfizer and Tanabe Mitsubishi and UCB, and has received research grants from AbbVie, Asahi Kasei, and Chugai. KF has received speaking fees and/or honoraria from Tanabe Mitsubishi, Bristol Myers, Eli Lilly, Chugai, Jansen, Pfizer, Ono, AbbVie, Ayumi, Astellas, Sanofi, Novartis, Daiichi Sankyo, Eisai, Asahi Kasei, Japan Blood Products Organization, and AstraZeneca, and has received research grants from Tanabe Mitsubishi, Bristol Myers, Eli Lilly, Chugai, AbbVie, Ayumi, Astellas, Sanofi, Eisai, Tsumura and Co., Asahi Kasei and AstraZeneca.